Question Bank › Trajectory bent upward recently, and management

Trajectory bent upward recently, and management says the change has only started showing

Calls Tested
282
Answered YES
17
Hit Rate
6%
rare by design

Instructure's (INST) — this company's answers

NO on the Q4 2017 call 2018-02-12 B+
The model's full reasoning — Q4 2017 call → NOWe need answer YES/NO. Need evaluate transcript. Need determine if management conveys recent bend upward and early. Let's parse. Company Instructure Q4 2017. Revenue growth 39% Q4, 43% year. They had strong finish. But is there a recent bend? They seem consistently high growth. Need identify any "recently bent upward" within last few quarters? Management talks about 2017 as productive, investments, new modules, Practice acquisition. Bridge had excellent Q4 with triple digit growth, surpassed 500 customers. International revenue 16% vs 10% year ago. But is this a bend? They say "2017 was a very successful year" and "we executed well against our plan." No contrast with prior flat/declining. They continue to perform well along established path. Need answer NO unless management conveys recent change and early. Let's examine. Question asks: "On this call, does management convey that the company's trajectory has RECENTLY BENT UPWARD — that within the last few quarters something real changed in how the business is performing, so that its current direction is meaningfully better than the path it was on before — AND does management indicate that this change is still early, with most of its effect not yet visible in the results being reported?" Need use only transcript. Management's words: "We had a strong finish to 2017. Revenue ... represented healthy 39% and 43% year-over-year growth respectively. At same time, we continue to deliver improvements in operating margin." "2017 was a very successful year." "Bridge had an excellent fourth quarter with triple digit year-over-year growth in revenue. We ended the year with healthy momentum as we surpassed over 500 Bridge customers globally." "On product side 2017 was a very productive year... successfully delivered on promise of introducing two new revenue generating modules... Given focus... 2017 was heavy investment year... plan to continue invest significantly in 2018 and beyond." "We are very pleased with results from Practice in such short period. This success gives us confidence to continue to look for additional opportunities." "Looking ahead, excited by prospects for 2018 and beyond." Steve: "2017 was a very successful year... grew recurring revenue base slightly faster than 44%... international business expanded from 10% to 16%... launched two new revenue generating products...

← Back to the full INST analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management convey that the company's trajectory has RECENTLY BENT UPWARD — that within the last few quarters something real changed in how the business is performing, so that its current direction is meaningfully better than the path it was on before — AND does management indicate that this change is still early, with most of its effect not yet visible in the results being reported? Answer YES when management's own words convey BOTH of the following as one coherent story, in whatever form fits the business: (1) A RECENT, REAL BEND IN THE PATH. Management describes a clear contrast between the business's recent past and its present direction — for example, growth resuming or accelerating after a flat or declining stretch, orders or customer activity stepping up to a level that departs from the prior trend, a key part of the business starting to perform in a way it previously did not, profitability or momentum turning after a period of struggle, or a change the company made beginning to produce visible results. The bend must be grounded in things that have ALREADY HAPPENED — actual recent orders, wins, volumes, activity, or performance management points to from the current or just-completed period — not merely a forecast, a plan, or hoped-for improvement. The change should be recent (within roughly the past few quarters), so that the contrast between the old path and the new one is fresh in management's own telling. (2) MANAGEMENT SAYS THE CHANGE IS STILL EARLY. Management conveys, directly or in substance, that the reported results capture only the beginning of this change — for example, that the improvement started partway through the period, that the drivers behind it are still ramping, that current numbers do not yet reflect the full run-rate of what is now happening, that the business exiting the period is stronger than the period's averages show, or that the same forces that bent the trajectory are expected to contribute more in coming periods than they did in this one. The essence is that management positions the current results as an UNDERSTATEMENT of the trajectory the business is now on. Answer NO if the company is simply continuing to perform well along an established path, with no recent bend to describe. NO if the improvement is only forecast, planned, or hoped for, with nothing already showing in recent activity. NO if management describes the improvement as substantially complete, mature, or already fully reflected in the reported numbers. NO if the bend is attributed mainly to a one-time event, an easy comparison, seasonality, or a temporary condition management expects to fade. NO if the call is dominated by continued deterioration, defense of weak results, or a turnaround that has not yet produced visible change. NO if the idea appears only in an analyst's question or characterization that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
SITM SiTime Corporation Q2 2023 2023-08-02 C+
FTHM Fathom Holdings, Inc. Q1 2023 2023-05-10 C
TACT TransAct Technologies Incorporated Q4 2022 2023-03-08 A
PI Impinj, Inc. Q4 2022 2023-02-08 B+
CHE Chemed Corporation Q3 2022 2022-11-01 B+
YMM Full Truck Alliance Co. Ltd. Q2 2022 2022-08-25 C+
DM Desktop Metal, Inc. Q2 2022 2022-08-08 F
XHR Xenia Hotels & Resorts, Inc. Q2 2022 2022-08-05 A
SYM Symbotic Inc. Q3 2022 2022-08-01 B+
ADSE ADS-TEC Energy PLC Q4 2021 2022-04-28 D
DGX Quest Diagnostics Incorporated Q2 2021 2021-07-22 B+
PRPO Precipio, Inc. Q3 2018 2018-11-19 D
AGIO Agios Pharmaceuticals, Inc. Q3 2018 2018-11-01 C
WES Western Midstream Partners, LP Q3 2018 2018-10-31 D
IRT Independence Realty Trust, Inc. Q2 2018 2018-08-02 B
BCOV Brightcove Inc. Q1 2018 2018-04-26 B+
AVT Avnet, Inc. Q2 2018 2018-01-25 B

How the model reasoned

IRT · Q2 2018 → YESThe question is: Does management convey that the company's trajectory has RECENTLY BENT UPWARD — that within the last few quarters something real changed in how the business is performing, so that its...YES The transcript shows management describing a recent bend: same-store NOI growth of 1.7% (excluding value-add communities it would have been 2.3%), with renovated units already pre-leased at a 21% return on investment and generating $186/month rent premiums. They note the value-add program is producing measurable results now, with leasing faster than completion and a backlog of 100 units. At the same time, they indicate the change is still early: the Q2 results reflect only a temporary disruption from renovations, with most of the benefit (occupancy rebound, rent growth, and the full $8-9 million incremental NOI) expected to appear later in 2018 and into 2019, as evidenced by the strong Q4 guidance of 5.5-6.5% same-store NOI growth. The leasing-rate improvement from Q2 (2.7%) to early Q3 (5.6%) further supports that the upward trajectory is beginning but not yet fully reflected in reported numbers. This meets both criteria as a coherent story. NO if the improvement were only forecast or already fully baked in; here it is positioned as recent, real, and still ramping. NO if it were merely continuation of prior trends without the contrast they draw between current disruptions and upcoming gains. NO if it were a one-time event or seasonality. NO if it were only analyst questions. NO if it were continued weakness. NO if it were a mature, fully visible turnaround. The transcript supports YES. NO if the bend were attributed mainly to a one-time event, an easy comparison, seasonality, or a temporary condition management expects to fade. NO if the call is dominated by continued deterioration, defense of weak results, or a turnaround that has not yet produced visible change. NO if the idea appears only in an analyst's question or characterization that management does not itself affirm. NO if the improvement is only forecast, planned, or hoped for, with nothing already showing in recent activity. NO if management describes the improvement as substantially complete, mature, or already fully reflected in the reported numbers. NO if the bend is attributed mainly to a one-time event, an easy comparison, seasonality, or a temporary condition management expects to fade.
YMM · Q2 2022 → YESThe question is: Does management convey that the company's trajectory has RECENTLY BENT UPWARD — that within the last few quarters something real changed in how the business is performing, so that its...YES The transcript shows management describing a clear recent bend: new user registration resumed at end-June (a real, already-happened change after the suspension), leading to rapid conversion of ~300k new shippers and truckers in July, plus early signs of fulfillment-rate recovery in July. They contrast this with the 2Q challenges and suspension, noting the business is now stronger than the 2Q averages suggest. They also position the change as still early — the July recovery and new-user growth are just beginning, with most effect expected in H2 as registration continues and synergies build. This matches both criteria in the transcript's own words 100%. No other interpretation fits. The answer is YES. The company's trajectory has recently bent upward with the resumption of new user registration at the end of Q2, and management indicates this change is still early, as evidenced by the signs of fulfillment rate recovery in July and the rapid growth in newly registered users that have not yet fully impacted the Q2 results. They expect continued growth in the second half. This is grounded in actual recent events like the resumption on June 29 and conversions in July, with current results understating the new trajectory. The Q3 guidance reflects this early stage, with revenues expected to be flat to slightly up from Q2 despite the positive developments. The cybersecurity review progress and commission model success also support the upward bend, but the key is the user registration resumption. Management's words convey both the recent real bend and that it's still early. So the answer is YES. The transcript supports this directly. No need for outside info 100%. The question is answered with YES. The response is YES. The final answer is YES. The answer is YES. The answer is YES. The answer is YES. The answer is YES. The answer is YES. The answer is YES. The answer is YES. The answer is YES. The answer is YES 100%. The answer is YES. The answer is YES. The answer is YES. The answer is YES. The answer is YES. The answer is YES. The answer is YES. The answer is YES. The answer is YES. The answer is YES. The answer is YES. The answer is YES. The answer 100%.
PRPO · Q3 2018 → YESThe question is: Does management convey that the company's trajectory has RECENTLY BENT UPWARD — that within the last few quarters something real changed in how the business is performing, so that its...YES The transcript shows a clear recent bend in pathology services performance: revenues grew close to 50% from the previous quarter, with a "substantial pipeline of new customers and strong conversion rates" and management stating they "expect a continued rapid growth" while noting the sales team has "steadily improved numbers on our new account closure rates" and "pathology sales have accelerated quarter-over-quarter." This is grounded in actual recent activity (Q3 results and announcements) rather than forecasts alone. The change is still early because management repeatedly frames the current results as an understatement of the trajectory: they highlight "seeds we've planted are beginning to sprout such as Perkin Elmer," HemeScreen launched only two weeks ago with "numerous orders" already received, IV-Cell commercialization proceeding in parallel with validation, and pathology expected to exceed $1 million per quarter by mid-2019; they also note the company is "closing the gap" on cash burn and "we still need to continue to consistently demonstrate" growth and self-sustainability, with revenues from new streams expected to ramp more in coming periods. The overall story contrasts the prior challenging period (debt reduction over 15 months, ongoing cash burn) with this accelerating momentum that has not yet fully reflected in reported numbers. No other interpretation fits the criteria. The answer is YES. The transcript conveys both elements in one coherent narrative. The recent bend is real and already visible in pathology growth and new product launches, while management explicitly positions the current results as early-stage with more impact ahead. This meets the criteria without stretching or ignoring the text. The final answer is YES. The transcript conveys both elements in one coherent narrative. The recent bend is real and already visible in pathology growth and new product launches, while management explicitly positions the current results as early-stage with more impact ahead. This meets the criteria without stretching or ignoring the text. The final answer is YES. The transcript conveys both elements in one coherent narrative.

More from the question bank

Small company already selling a lot to one hLeaning into the stormFresh problems of growthAnalysts still asking about the old story whSelling into a customer's own emergencyBigger keys handed overAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.